Literature DB >> 26912916

Dinutuximab and Panobinostat.

Ashley Chasick1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 26912916      PMCID： PMC4750825          DOI： 10.1310/hpj5009-767

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  31 in total

1.  Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Authors:  Enrique M Ocio; Julio Dávila; Juan-Carlos Caballero; Sara Alonso; Verónica González de la Calle; Ramón García-Sanz; Lucien Gazi; Socrates Opio; Mónica Jiménez; Jesús F San-Miguel; María-Victoria Mateos
Journal:  Haematologica       Date:  2015-03-20       Impact factor: 9.941

2.  Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Authors:  Jesús F San-Miguel; Paul G Richardson; Andreas Günther; Orhan Sezer; David Siegel; Joan Bladé; Richard LeBlanc; Heather Sutherland; Monika Sopala; Kaushal K Mishra; Song Mu; Priscille M Bourquelot; María Victoria Mateos; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

3.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

4.  Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Authors:  A L Yu; M M Uttenreuther-Fischer; C S Huang; C C Tsui; S D Gillies; R A Reisfeld; F H Kung
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

5.  Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Authors:  Andrew L Gilman; M Fevzi Ozkaynak; Katherine K Matthay; Mark Krailo; Alice L Yu; Jacek Gan; Adam Sternberg; Jacquelyn A Hank; Robert Seeger; Gregory H Reaman; Paul M Sondel
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

6.  A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Authors:  Jhanelle E Gray; Eric Haura; Alberto Chiappori; Tawee Tanvetyanon; Charles C Williams; Mary Pinder-Schenck; Julie A Kish; Jenny Kreahling; Richard Lush; Anthony Neuger; Leticia Tetteh; Angela Akar; Xiuhua Zhao; Michael J Schell; Gerold Bepler; Soner Altiok
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

7.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

Authors:  B M Mueller; C A Romerdahl; S D Gillies; R A Reisfeld
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

8.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

Review 9.  Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Authors:  Nora Berois; Eduardo Osinaga
Journal:  Front Oncol       Date:  2014-05-23       Impact factor: 6.244

10.  Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Authors:  S Bauer; R A Hilger; T Mühlenberg; F Grabellus; J Nagarajah; M Hoiczyk; A Reichardt; M Ahrens; P Reichardt; S Grunewald; M E Scheulen; A Pustowka; E Bock; M Schuler; D Pink
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.